Blood-based Amyloid and Tau Biomarker Tests For Alzheimer’s Disease

Publisher： Bentham Science Publishers

E-ISSN： 2213-3860|4|1|4-13

ISSN： 2213-3852

Source： Neuroscience and Biomedical Engineering, Vol.4, Iss.1, 2016-03, pp. : 4-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amyloid and tau in the brain in sporadic Alzheimer’s disease: defining the chicken and the egg

By Hawkes Cheryl   Carare Roxana   Weller Roy  

Acta Neuropathologica, Vol. 127, Iss. 4, 2014-04 ,pp. : 617-618

Springer Publishing Company

Access to resources Recommend Favorite

Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?

By  

Current Alzheimer Research, Vol. 13, Iss. 4, 2016-04 ,pp. : 403-412

Bentham Science Publishers

Access to resources Recommend Favorite

Amyloid-&bgr; Peptides, Alzheimer's Disease and the Blood-brain Barrier

By  

Current Alzheimer Research, Vol. 10, Iss. 10, 2013-12 ,pp. : 1015-1033

Bentham Science Publishers

Access to resources Recommend Favorite

Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques

By  

Neuroscience and Biomedical Engineering, Vol. 1, Iss. 2, 2013-09 ,pp. : 92-101

Bentham Science Publishers

Access to resources Recommend Favorite

Amyloid precursor protein and tau transgenic models of Alzheimer’s disease: insights from the past and directions for the future

By Sahara Naruhiko   Lewis Jada  

Future Neurology, Vol. 5, Iss. 3, 2010-05 ,pp. : 411-420

Future Medicine

Access to resources Recommend Favorite